Anti-IL-31 receptor monoclonal antibody
Nemolizumab
Brand names: Nemluvio
Adult dose
Dose: Loading 60mg SC; then 30mg SC every 4 weeks
Route: SC
Frequency: q4w
Clinical pearls
- Moderate-severe atopic dermatitis or prurigo nodularis; specialist dermatology
Contraindications
- Hypersensitivity
Side effects
- Headache
- Eczema
- Atopic dermatitis flare
- Asthma exacerbation
- Injection site reactions
Interactions
- Live vaccines
Monitoring
- EASI/IGA
- Asthma symptoms
Reference: BNF; NICE TA1056; SmPC; https://bnf.nice.org.uk/drugs/nemolizumab/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- Revised Original International Autoimmune Hepatitis Score (IAIHG) · Autoimmune Liver Disease
- Ho Index for Predicting Response to Medical Therapy in IBD · Inflammatory Bowel Disease
- Myasthenia Gravis Activities of Daily Living (MG-ADL) Scale · Neuromuscular
- Rh(D) Immune Globulin Dosage for Maternal-Fetal Haemorrhage · Haematology in Pregnancy
- AREDS Classification of Age-related Macular Degeneration · Macular Degeneration
- Diabetic Macular Oedema (DMO) Classification · Diabetic Retinopathy
Pathways
- Suspicious Pigmented Lesion — Melanoma Pathway · NICE NG14 2015 / BAD
- Cellulitis and Erysipelas · NICE NG141 2019 / CREST
- Psoriasis — Severity Assessment and Step-Up Therapy · NICE NG153 2019 / BAD
- Atopic Eczema — Assessment and Step-Up Therapy · NICE NG95 2023
- Urticaria and Angioedema · BSACI / EAACI Guidelines 2022
- Acne Vulgaris — Grading and Treatment · NICE NG198 2021 / BAD